Eva Dombi

28PUBLICATIONS
137CO-AUTHORS
Molecular targetsPredictive and prognostic markersNeurology and neuromuscular diseasesGene and molecular therapyNeonatology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|Sep 02, 2026
KRAS is required for plexiform neurofibroma formation and represents a targetable vulnerability in established tumors.

|Aug 22, 2026
Risk of developing malignant peripheral nerve sheath tumors in patients with neurofibromatosis 1 receiving MEK inhibitor treatment for plexiform neurofibromas.

|Aug 01, 2026
Malignant peripheral nerve sheath tumor development during MEK inhibitor treatment: A pre-clinical study and a clinical case series.

|May 13, 2026
Valosin-Containing Protein Contributes to Plexiform Neurofibroma Formation and Represents a Novel Therapeutic Target.

|Jan 08, 2026
SARC031: A Phase II Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST).

AeRang Kim, Karla V Ballman, Pamela L Wolters

|Dec 31, 2025
Malignant peripheral nerve sheath tumors in neurofibromatosis type 1 arise from distinct nodular lesions: A retrospective imaging analysis.

Johannes Salamon, Brigitte C Widemann, Andrea M Gross

Pageof 5

Frequent Collaborators

13 joint publications

Brigitte Widemann

11 joint publications

Andrea M Gross

7 joint publications

AeRang Kim

6 joint publications

Russell Taylor Sundby